- Previous Close
14.32 - Open
14.45 - Bid 10.64 x 200
- Ask 14.32 x 800
- Day's Range
14.06 - 14.87 - 52 Week Range
6.18 - 18.51 - Volume
863,536 - Avg. Volume
1,326,164 - Market Cap (intraday)
1.389B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.50 - Earnings Date Mar 19, 2025 - Mar 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
27.25
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
ars-pharma.comRecent News: SPRY
View MorePerformance Overview: SPRY
Trailing total returns as of 1/30/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SPRY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SPRY
View MoreValuation Measures
Market Cap
1.39B
Enterprise Value
1.18B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
537.66
Price/Book (mrq)
6.91
Enterprise Value/Revenue
461.16
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-16.22%
Return on Equity (ttm)
-22.41%
Revenue (ttm)
2.57M
Net Income Avi to Common (ttm)
-49.1M
Diluted EPS (ttm)
-0.50
Balance Sheet and Cash Flow
Total Cash (mrq)
204.62M
Total Debt/Equity (mrq)
0.05%
Levered Free Cash Flow (ttm)
-31.67M